<DOC>
	<DOCNO>NCT00722592</DOCNO>
	<brief_summary>The objective study compare progression-free survival ( PFS ) , base upon investigator assessment use Response Evaluation Criteria In Solid Tumors version 1.0 ( RECIST 1.0 ) clinical finding , participant platinum-resistant ovarian cancer receive combination therapy vintafolide pegylated liposomal doxorubicin ( PLD/Doxil®/Caelyx® ) subject platinum-resistant ovarian cancer receive PLD alone .</brief_summary>
	<brief_title>Platinum Resistant Ovarian Cancer Evaluation Doxil Vintafolide ( MK-8109 , EC145 ) Combination Therapy ( 8109-009 , EC-FV-04 )</brief_title>
	<detailed_description>This Phase II clinical trial evaluate efficacy safety combination vintafolide pegylated liposomal doxorubicin ( PLD ; available United States Doxil® outside United States Caelyx® ) compare PLD alone . Vintafolide drug specifically design enter cancer cell via folate vitamin receptor ( FR ) . Experimental evidence show target receptor express virtually ovarian cancer . Early clinical evidence small number Phase I subject subset subject on-going single-arm Phase II study suggest vintafolide may antitumor effect woman advance ovarian cancer generally well-tolerated . This evidence suggest vintafolide may useful chemotherapy advanced ovarian cancer . Patients center EC20 image capability also undergo image folate receptor ( FR- ) target investigational diagnostic agent EC20 screening period ass uptake agent tumor . This non-invasive procedure provide additional information utility EC20 image identify subject FR molecular `` target '' treatment vintafolide therapy .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Vinca Alkaloids</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>To qualify randomization treatment follow criterion must meet : Subjects must sign approve informed consent form Subjects must ≥ 18 year age Subjects must pathologyconfirmed epithelial ovarian , fallopian tube , primary peritoneal carcinoma Subjects must platinumresistant ovarian cancer , platinumresistant define disease respond primary platinum therapy progress within 6 month disease progress within 6 month complete secondary platinum therapy Subjects must least single ( RECISTdefined ) measurable lesion radiological evaluation conduct four week prior begin study therapy ( EC145 and/or PLD ) . Subjects must prior debulking surgery Subjects must receive prior platinumbased chemotherapy must receive 2 prior systemic cytotoxic regimen . Subjects allow receive , required receive , one additional noncytotoxic regimen management recurrent persistent disease . Noncytotoxic ( biologic cytostatic ) agent include , limited , monoclonal antibody , cytokine , smallmolecule inhibitor signal transduction . Subjects must Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Subjects must recover ( baseline/stabilization ) prior cytotoxic therapyassociated acute toxicity . Subjects recover noncytotoxic therapyassociated toxicity `` control '' noncytotoxic therapy toxicity ( e.g. , vascular endothelial growth factorrelated hypertension ) enter trial drug washout period 4 half life Subjects must adequate organ function include : 1 . Bone Marrow Reserve : Absolute neutrophil count ( ANC ) ≥ 1.5x10^9/L prior treatment . Subjects maintenance dos granulocyte colony stimulating factor ( GCSF ) eligible . Platelets ≥ 100x10^9/L hemoglobin ≥ 9 g/dL . 2 . Hepatic : Total bilirubin level &lt; 1.5 x ULN alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , gamma glutamyl transferase ( GGT ) , alkaline phosphatase level &lt; 2.5 x ULN . 3 . Renal : Serum creatinine level ≤ 1.5 x ULN creatinine clearance ≥ 50 mL/min/1.73m^2 subject serum creatinine level 1.5 x ULN . 4 . Cardiac : Left ventricular ejection fraction ( LVEF ) equal great institutional low limit normal . LVEF must elevate within 90 day prior Cycle 1 Day 1 Subjects childbearing potential must : 1 . Have negative serum pregnancy test prior initiation therapeutic regimen 2 . Practice effective method birth control ( e.g. , oral , transdermal injectable contraceptive , intrauterine device , doublebarrier contraception , diaphragm spermicidal jelly ) duration participation trial 3 month follow last dose study drug . The presence follow exclude subject study : Diagnosis tumor lowmalignant potential Prior exposure PLD anthracycline therapy Prior exposure FRtargeted therapy ( EC145 , EC0225 , farletuzumab , etc ) Prior therapy mouse antibody Prior therapy vinorelbine ( Navelbine® ) vincacontaining compound Prior abdominal pelvic radiation therapy , radiation therapy &gt; 10 % bone marrow , prior radiation therapy within past 3 year breast/sternum , dermal lesion , head neck Recent ( i.e. , ≤ 6 week ) history abdominal surgery peritonitis Serious comorbidities ( determined investigator ) , limited , active congestive heart failure recent myocardial infarction . Subjects require antifolate therapy management comorbid condition ( e.g. , rheumatoid arthritis ) exclude trial . Pregnancy Concurrent malignancy history cancer ( except noninvasive skin cancer ) within last 5 year Symptomatic central nervous system metastasis Other concurrent chemotherapy , immunotherapy , radiotherapy , ancillary therapy consider investigational ( i.e. , use nonapproved indication ( ) context research investigation ) . Use low dose corticosteroid therapy ( nausea prophylaxis , etc ) acceptable ; however , concomitant tamoxifen therapy . Supportive care measure allow .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>cancer</keyword>
	<keyword>ovarian</keyword>
	<keyword>platinum-resistant</keyword>
	<keyword>Phase II</keyword>
	<keyword>EC145</keyword>
	<keyword>EC20</keyword>
</DOC>